ReviewExploration (Beijing, China)2023
Recent development of pH-responsive theranostic nanoplatforms for magnetic resonance imaging-guided cancer therapy.
Review in Exploration (Beijing, China), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Eudragit-Based Nanoparticles for Oral Drug Delivery.Pharmaceutics · 2026Review
- From conceptual design to translational progress: Emerging advances in intelligent microneedles for biomedical applications.Acta pharmaceutica Sinica. B · 2026Review
- An atom-edged magnetic nanomotor for cancer mechanotherapy.iScience · 2026Article
- Bioactive manganese oxide nanoassembly as a highly sensitive magnetic resonance imaging probe for grading diagnosis of liver injury.Journal of nanobiotechnology · 2026Article
- Next-generation dynamic and combinatorial nanotherapies for liver cancer: mechanisms, current advances and future perspectives.Journal of nanobiotechnology · 2026Review
- Antibody-Empowered Nanomedicine for Precise Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Advancements in nanomaterials for the treatment and management of vascular surgeries: from drug delivery to biomedical implants.Frontiers in bioengineering and biotechnology · 2026Review
- Rutin-encapsulated manganese carbonate nanoparticles for 'liver-dark/tumor-bright' magnetic resonance imaging and inhibition of breast cancer with liver metastases.Regenerative biomaterials · 2026Article
- pH-responsive 2D niobium carbide nanosheets for targeted circPUM1 siRNA delivery in ovarian cancer therapy.Materials today. Bio · 2025Article
- Advanced strategies of covalent organic framework nanomedicines in targeting and overcoming biological barriers.Asian journal of pharmaceutical sciences · 2025Review
- Convertible ROS Nanocatalyst/Eliminator for Enhancing Tumor Radio-Immunotherapy and Relieving Radiation Enteritis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Sorafenib-loaded metal-organic framework nanoparticles for anti-hepatocellular carcinoma effects through synergistically potentiating ferroptosis and remodeling tumor immune microenvironment.Materials today. Bio · 2025Article
- A Real-Time Cell Death Self-Reporting Theranostic Agent for Dynamic Optimization of Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Advances in nanotechnology for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease.Asian journal of pharmaceutical sciences · 2025Review
- Skin-compatible CarbopolMacromolecular materials and engineering · 2025Article
- Tailoring cell-inspired biomaterials to fuel cancer therapy.Materials today. Bio · 2025Review
- Stimuli-Responsive Nodal Dual-Drug Polymer Nanoparticles for Cancer Therapy.International journal of nanomedicine · 2025Article
- Design of pH-Responsive Nanomaterials Based on the Tumor Microenvironment.International journal of nanomedicine · 2025Review
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- Review and Future Perspectives of Stimuli-Responsive Bridged Polysilsesquioxanes in Controlled Release Applications.Polymers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acidic characteristic of the tumor site is one of the most well-known features and provides a series of opportunities for cancer-specific theranostic strategies. In this regard, pH-responsive theranostic nanoplatforms that integrate diagnostic and therapeutic capabilities are highly developed. The fluidity of the tumor microenvironment (TME), with its temporal and spatial heterogeneities, makes noninvasive molecular magnetic resonance imaging (MRI) technology very desirable for imaging TME constituents and developing MRI-guided theranostic nanoplatforms for tumor-specific treatments. Therefore, various MRI-based theranostic strategies which employ assorted therapeutic modes have been drawn up for more efficient cancer therapy through the raised local concentration of therapeutic agents in pathological tissues. In this review, we summarize the pH-responsive mechanisms of organic components (including polymers, biological molecules, and organosilicas) as well as inorganic components (including metal coordination compounds, metal oxides, and metal salts) of theranostic nanoplatforms. Furthermore, we review the designs and applications of pH-responsive theranostic nanoplatforms for the diagnosis and treatment of cancer. In addition, the challenges and prospects in developing theranostic nanoplatforms with pH-responsiveness for cancer diagnosis and therapy are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.